Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/14/2019 |
| Start Date: | June 2013 |
| End Date: | February 20, 2018 |
A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in
combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is
an open-label, 2-stage study designed to determine the recommended dose level of bendamustine
in combination with brentuximab vedotin. The study will assess the safety profile of the
combination treatment and determine what proportion of patients achieve a complete remission.
combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is
an open-label, 2-stage study designed to determine the recommended dose level of bendamustine
in combination with brentuximab vedotin. The study will assess the safety profile of the
combination treatment and determine what proportion of patients achieve a complete remission.
Inclusion Criteria:
- Histopathological diagnosis of classical Hodgkin lymphoma
- Failed standard front-line therapy
- Measurable disease of at least 1.5 cm as documented by radiographic technique
- Eastern Cooperative Oncology Group performance status less than or equal to 2
Exclusion Criteria:
- Received prior salvage therapy, including radiotherapy
- Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not
completed 4 weeks prior to first dose of study drug
- Concurrent use of other investigational agents
We found this trial at
13
sites
Click here to add this to my saved trials
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
Denver, Colorado 80218
720-754-4800
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
Click here to add this to my saved trials
Click here to add this to my saved trials
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials